New CAR T cell therapy for treating childhood brain tumors
Next Generation GPC2-CARs for Medulloblastoma
['FUNDING_OTHER'] · STANFORD UNIVERSITY · NIH-11051634
This study is testing a new type of treatment for children with medulloblastoma, a common brain tumor, by using specially designed immune cells to target the cancer while being kinder to their healthy cells.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-11051634 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel CAR T cell therapy targeting GPC2, a protein overexpressed in medulloblastoma, the most common malignant brain tumor in children. By using a specialized approach that enhances the effectiveness of CAR T cells, the research aims to create a targeted treatment that minimizes toxicity compared to traditional therapies. The methodology involves optimizing CAR T cells to specifically attack cancer cells while sparing normal tissues, potentially leading to better outcomes for young patients with high-risk tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years diagnosed with medulloblastoma, particularly those with high-risk or recurrent forms of the disease.
Not a fit: Patients with non-cancerous conditions or those diagnosed with other types of brain tumors not expressing GPC2 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for children with medulloblastoma.
How similar studies have performed: Previous research has shown promising results with CAR T cell therapies in pediatric brain tumors, indicating potential for success with this novel approach.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MACKALL, CRYSTAL — STANFORD UNIVERSITY
- Study coordinator: MACKALL, CRYSTAL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Brain Cancer